cPLA2 Inhibiting Silicone-based Gel AVX001

Preferred Label : cPLA2 Inhibiting Silicone-based Gel AVX001;

NCIt synonyms : (6E,10Z,13Z,16Z,19Z)-1,1,1-trifluoro-4-thiadocosa-6,10,13,16,19-pentaen-2-one; Silicone-based Gel AVX001;

NCIt related terms : AVX-001;

NCIt definition : A topical preparation composed of a silicone gel containing a docosahexaenoic acid derivative and cytosolic group IVA phospholipase A2 alpha (cytosolic phospholipase A2 group IVA; cPLA2a; GIVA cPLA2; Group IVA cPLA2) inhibitor, with potential anti-inflammatory activity. Upon topical application to the affected site(s), the cPLA2 inhibiting silicone-based gel AVX001 binds to and inhibits the activity of cPLA2alpha. This may inhibit cPLA2alpha-mediated inflammation. cPLA2alpha catalyzes the release of arachidonic acid from glycerophospholipids and plays a key role in various inflammatory diseases. It is overexpressed in certain cancer cells and may play a key role in proliferation, migration, and chemo-resistance.;

UNII : G8333V26KK;

CAS number : 300553-18-8;

Molecule name : AVX-001; AVX 001;

NCI Metathesaurus CUI : CL1773945;

Details

Origin ID

C185597;

UMLS CUI

C3659552;

Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- AVX001 [MeSH Supplementary Concept]
- AVX001 [MeSH concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Cytosolic Phospholipase A2 Group IV [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients